These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37691291)

  • 21. Non-Alcoholic Fatty Liver Disease and Vascular Disease.
    Forlano R; Mullish BH; Nathwani R; Dhar A; Thursz MR; Manousou P
    Curr Vasc Pharmacol; 2021; 19(3):269-279. PubMed ID: 32188385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials.
    Yeh ML; Yu ML
    Clin Mol Hepatol; 2023 Oct; 29(4):969-972. PubMed ID: 37718552
    [No Abstract]   [Full Text] [Related]  

  • 23. [Emphasis on clinical study of heterogeneity of non-alcoholic fatty liver disease].
    Huang LJ; Xu YH; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):193-197. PubMed ID: 32306650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes.
    Käräjämäki AJ; Bloigu R; Kauma H; Kesäniemi YA; Koivurova OP; Perkiömäki J; Huikuri H; Ukkola O
    Metabolism; 2017 Jan; 66():55-63. PubMed ID: 27423871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases.
    Motamed N; Rabiee B; Poustchi H; Dehestani B; Hemasi GR; Khonsari MR; Maadi M; Saeedian FS; Zamani F
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):31-38. PubMed ID: 27597641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions.
    Lee JI
    Gut Liver; 2022 Jul; 16(4):497-498. PubMed ID: 35843683
    [No Abstract]   [Full Text] [Related]  

  • 27. Association of changes in body mass index and waist circumference with cardiovascular risk in non-alcoholic fatty liver disease: A nationwide study.
    Jang SY; Kim HJ; Chang JY
    Dig Liver Dis; 2023 Nov; 55(11):1509-1514. PubMed ID: 37419727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis.
    Pacana T; Fuchs M
    Clin Liver Dis; 2012 Aug; 16(3):599-613. PubMed ID: 22824483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk?
    Montecucco F; Mach F
    Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):301-7. PubMed ID: 19075784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular risk estimation in non alcoholic fatty liver disease.
    Romdhane H; Cheikh M; Ennaifer R; Mahmoud Y; Bougassas W; Ben Nejma H; Bel Hadj N
    Tunis Med; 2016 Dec; 94(12):839. PubMed ID: 28994882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-Alcoholic Fatty Liver Disease and HIV/AIDS: A New Way of Modulation of Cardiovascular Risk.
    Ahmed MH; Husain NE; Malik A; Woodward C; Mital D
    AIDS Rev; 2017; 19(4):190-197. PubMed ID: 29271970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease.
    Marti-Aguado D; Ten-Esteve A; Baracaldo-Silva CM; Crespo A; Coello E; Merino-Murgui V; Fernandez-Paton M; Alfaro-Cervello C; Sánchez-Martín A; Bauza M; Jimenez-Pastor A; Perez-Girbes A; Benlloch S; Pérez-Rojas J; Puglia V; Ferrández A; Aguilera V; Latorre M; Monton C; Escudero-García D; Bosch-Roig I; Alberich-Bayarri Á; Marti-Bonmati L
    Front Endocrinol (Lausanne); 2023; 14():1213441. PubMed ID: 37600695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter to the Editor: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality.
    Li Z; Zhang L; Li J
    Hepatology; 2023 Jul; 78(1):E4-E5. PubMed ID: 36932712
    [No Abstract]   [Full Text] [Related]  

  • 37. Update on the treatments of non-alcoholic fatty liver disease (NAFLD).
    Quercioli A; Montecucco F; Mach F
    Cardiovasc Hematol Disord Drug Targets; 2009 Dec; 9(4):261-70. PubMed ID: 19751186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: Conceptual changes for clinicians, researchers and patients.
    Lin SZ; Chen YW; Fan JG
    J Dig Dis; 2020 Nov; 21(11):604-609. PubMed ID: 32975050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease-simply associated or more complicated?
    Demirtas CO; Yilmaz Y
    Aliment Pharmacol Ther; 2021 Jun; 53(11):1228-1229. PubMed ID: 33961704
    [No Abstract]   [Full Text] [Related]  

  • 40. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
    Loomba R; Wong VW
    Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.